GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic (semaglutide) and Wegovy (semaglutide) injection pens, available to GoodRx users.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117268209/en/

GoodRx for Weight Loss

“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration, home delivery capabilities, and transparent pricing in one seamless experience, GoodRx is creating a higher standard for affordability and trust in weight loss care.”

A Seamless Path to Safe, FDA-Approved GLP-1 Treatment for Weight Loss

GoodRx for Weight Loss is a comprehensive, direct-to-consumer telemedicine subscription built to simplify every step of the GLP-1 treatment journey, from consultation to prescription to fulfillment.

GoodRx for Weight Loss features include:

• GoodRx savings on brand medications, including the lowest cash prices available for any FDA-approved GLP-1 medications for weight loss treatment.
• Transparent pricing so consumers know what they’ll pay upfront, with no hidden fees.
• Flexible fulfillment options, including in-store pick-up at nearly all retail pharmacy locations nationwide for Wegovy or Zepbound (tirzepatide) pens, or convenient home delivery for the Zepbound vial formulation via LillyDirect.
• Virtual consultations with licensed healthcare providers to determine eligibility and if appropriate, write a prescription for FDA-approved GLP-1 treatments for weight loss.
• Ongoing clinical support to track progress, manage side effects, and adjust treatment as needed.
• A personalized, consumer-first experience that prioritizes safety, affordability, and convenience.

The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January 2026, with a standard price of $119 beginning on February 1, 2026. Medications are priced separately, allowing customers to only pay for what they need.